NANJING, China, July 9, 2026 /PRNewswire/ — InxMed Co., Ltd (“InxMed”), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results of ifebemtinib (IN10018), a highly…
Source: prnewswire
Country: United States